
|Articles|November 21, 2017
OmniComm Systems Signs Letter of Intent to Acquire Assets of Algorithm and its Algorics
Advertisement
OmniComm Systems, Inc. and Algorithm, Inc. have signed a letter of intent, under which OmniComm will acquire assets and assume liabilities of Algorics to build upon RBM and data analytics. By combining forces, the companies expect increased operating efficiency, strengthened traction in the risk-based approach solution area, new marketing opportunities, an expanded portfolio of electronic data capture solutions for the clinical trials industry, and will provide OmniComm with access to advanced analytics and algorithms.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
3
ACT Brief: AI-Driven Enrollment Results, Statistician Standards in Early Phase, and RNA Editing for Kidney Disease
4
SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment
5




